RAMP vs KOD Comparison

LiveRamp Holdings Inc is a technology company that empowers marketers and media owners to deliver and measure marketing performance everywhere it matters. Its data collaboration network seamlessly unites data across advertisers, ad tech platforms, publishers, data providers, and commerce media networks, unlocking insights that deliver transformational consumer experiences and drive measurable business outcomes. The group's platform is engineered for AI agent accessibility, facilitating autonomous data collaboration between the specialized AI agents utilized by customers and partners and the networked platform. It generates the geographic revenue from the United States, followed by Europe, Asia-Pacific ("APAC"), and Other.

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.